Group A (n=20) | Group B (n=16) | Group C (n=25) | Group D (n=38) | Controls (n=16) | p Value | |
Wall area (%) | 70.9 (1.6) | 70.4 (1.6) | 69.9 (1.4) | 70.3 (1.1) | 63.7 (1.0) | 0.009 |
Wall area/BSA (mm2/m2) | 12.5 (0.9) | 11.1 (1.3) | 13.1 (0.8) | 12.1 (0.6) | 13.9 (1.1) | 0.35 |
Lumen area/BSA (mm2/m2) | 5.4 (0.6) | 4.7 (0.6) | 5.7 (0.5) | 5.4 (0.4) | 7.9 (0.5) | 0.008 |
Total area/BSA (mm2/m2) | 17.9 (1.4) | 15.9 (1.8) | 18.8 (1.2) | 17.5 (1.0) | 21.8 (1.5) | 0.10 |
Data expressed as mean (SEM).
Intergroup comparisons: one-way ANOVA with Tukey test to compare all pairs of columns.
Group A, patients with severe asthma with a concordant asthma control score and eosinophilic inflammation with a significantly greater bronchodilator response; group B, patients with severe asthma who were predominantly women with high body mass index and evidence of a high asthma control score but very little eosinophilic airway inflammation; group C, patients with severe asthma with a predominantly high asthma control score and very little eosinophilic airway inflammation; group D, patients with severe asthma with predominantly eosinophilic airway inflammation and significantly low asthma control score.
BSA, body surface area.